ArticleMolecular biology reports2012
Methylated promoters of genes encoding protocadherins as a new cancer biomarker family.
Article in Molecular biology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Loss of long-range co-expression is a common feature in cancer.NPJ systems biology and applications · 2026Article
- COP1 Acts as a Ubiquitin Ligase for PCDH9 Ubiquitination and Degradation in Human Glioma.Molecular neurobiology · 2022Article
- The role of epigenetic modifications, long-range contacts, enhancers and topologically associating domains in the regulation of glioma grade-specific genes.Scientific reports · 2021Article
- PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.International journal of hematology · 2020Article
- Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma.Oncology reports · 2019Article
- MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9.OncoTargets and therapy · 2019Article
- Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma.Cancer management and research · 2019Article
- Hypermethylation of protocadherin γ subfamily A12 and solute carrier family 19 A 1 promoters contributes to the occurrence and metastasis of colorectal cancer.Oncology letters · 2018Article
- Epigenetic-Mediated Downregulation of μ-Protocadherin in Colorectal Tumours.Gastroenterology research and practice · 2015Article
- Effects on specific promoter DNA methylation in zebrafish embryos and larvae following benzo[a]pyrene exposure.Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protocadherins are a major subfamily of the cadherin superfamily. Their functions and intracellular signal transduction are poorly understood, although some have been explored in nervous system development. However, recent researches have shown that protocadherins frequently act as tumor suppressor genes (TSGs) and inactivation of these genes through promoter methylation is closely correlated with tumor development. Furthermore, these methylated protocadherins may serve as tumor biomarkers in various body fluids, stool and scrapings not only for early cancer diagnosis, but also for assessing prognosis and monitoring response to therapy. Thus, methylated promoters of genes encoding protocadherins show promise as a new cancer biomarker family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.